Basal | Follow-up | P | Basal | Follow-up | P | Basal | Follow-up | P | |
---|---|---|---|---|---|---|---|---|---|
N | 107 | 107 | – | 53 | 53 | – | 37 | 37 | |
Recipient data | |||||||||
Mean age (years) | 51.3 ± 5.9 | – | – | 50.5 ± 5.5 | – | – | 51.3 ± 5.5 | – | – |
Sex, male (%) | 72 (67.3) | – | – | 34 (64.1) | – | – | 24 (64.9) | – | – |
BMI (kg/m2) | 25.5 ± 1.7 | 24.9 ± 1.4 | 0.010 | 27.8 ± 1.5* | 26.2 ± 1.6* | 0.001 | 27.9 ± 1.8* | 27.4 ± 1.9*§ | 0.279 |
Aetiology of heart failure | |||||||||
Myocardial ischemia, n (%) | 50 (46.7) | – | – | 27 (51.0) | – | – | 19 (51.3) | – | – |
Dilated cardiomyopathy, n (%) | 44 (41.1) | – | – | 20 (37.7) | – | – | 14 (37.8) | – | – |
Other, n (%) | 13 (12.1) | – | – | 6 (11.3) | – | – | 4 (10.9) | – | – |
Cardiovascular risk factors | |||||||||
Hypertension, n (%) | 33 (30.8) | – | – | 25 (47.2)* | – | – | 16 (43.2)* | – | – |
Dyslipidemia, n (%) | 21 (19.6) | – | – | 16 (30.2)* | – | – | 12 (32.4)* | – | – |
Family history of CAD, n (%) | 23 (21.5) | – | – | 18 (33.9)* | – | – | 13 (35.1)* | – | – |
Smoking history, n (%) | 13 (12.1) | – | – | 8 (15.1) | – | – | 5 (13.5) | – | – |
Diabetes duration, years | – | – | – | 14.6 ± 2.2 | – | – | 14.7 ± 3.1 | – | – |
Laboratory analyses | |||||||||
Plasma glucose (mg/dl) | 91.1 ± 6.4 | 91.7 ± 8.8 | 0.507 | 150.1 ± 12.1* | 137.1 ± 7.2* | 0.001 | 155.2 ± 26.2* | 180.9 ± 25.4*§ | 0.001 |
HbA1c (%) | 5.7 ± 0.9 | 5.8 ± 0.6 | 0.223 | 6.8 ± 1.2* | 6.5 ± 0.4* | 0.177 | 6.8 ± 1.1* | 8.2 ± 0.6*§ | 0.001 |
Cholesterol (mg/dl) | 159.8 ± 22.6 | 153.6 ± 17.4 | 0.013 | 173.9 ± 21.3* | 164.5 ± 27.1* | 0.039 | 177.1 ± 24.3* | 183.7 ± 15.2*§ | 0.233 |
LDL-cholesterol (mg/dl) | 94.5 ± 15.9 | 89.4 ± 14.6 | 0.016 | 95.8 ± 29.3 | 89.1 ± 13.8 | 0.141 | 97.2 ± 21.7 | 106.9 ± 14.9*§ | 0.671 |
HDL-cholesterol (mg/dl) | 40.91 ± 2.5 | 40.3 ± 2.5 | 0.051 | 39.8 ± 3.5* | 40.2 ± 2.9 | 0.536 | 38.8 ± 3.7* | 38.3 ± 3.1*§ | 0.585 |
Triglycerides (mg/dl) | 124.13 ± 28.1 | 119.5 ± 27.4 | 0.019 | 191.7 ± 22.4* | 175.2 ± 21.4* | 0.001 | 193.9 ± 22.5* | 197.8 ± 15.2* | 0.278 |
Creatinine (mg/dl) | 1.1 ± 0.11 | 1.0 ± 0.44 | 0.421 | 1.1 ± 0.41 | 1.1 ± 0.81 | 0.523 | 1.1 ± 0.21 | 1.1 ± 0.58 | 0.446 |
Heart failure therapy | |||||||||
ACEIs, n (%) | 70 (65.4%) | 71 (66.3) | 0.236 | 33 (62.3%) | 36 (67.9) | 0.298 | 24 (64.9%) | 24 (64.9%) | 0.362 |
Lisinopril 5 mg, n (%) | 9 (12.8%) | 7 (9.9%) | 4 (12.2%) | 4 (11.1%) | 3 (12.5%) | 3 (12.5%) | |||
10 mg, n (%) | 14 (20%) | 18 (25.3%) | 7 (21.3%) | 8 (22.2%) | 5 (20.8%) | 6 (25%) | |||
20 mg, n (%) | 11 (15.7%) | 10 (14.1%) | 5 (15.2%) | 5 (13.8%) | 3 (12.5%) | 2 (8.3%) | |||
Enalapril 5 mg, n (%) | 10 (14.3) | 8 (11.3%) | 5 (15.2%) | 5 (13.8%) | 4 (16.7%) | 4 (16.7%) | |||
10 mg, n (%) | 16 (22.9%) | 19 (26.8%) | 7 (21.3%) | 10 (27.8%) | 6 (25%) | 7 (29.2%) | |||
20 mg, n (%) | 10 (14.3%) | 9 (12.7%) | 5 (15.2%) | 4 (11.1%) | 3 (12.5%) | 2 (8.3%) | |||
ARBs, n (%) | 30 (28.1%) | 36 (33.7) | 0.457 | 12 (22.6%) | 17 (32.1) | 0.456 | 11 (29.7%) | 13 (35.1) | 0.473 |
Losartan 50 mg, n (%) | 6 (20%) | 6 (16.7%) | 2 (16.7%) | 2 (11.8%) | 2 (18.2%) | 2 (15.4%) | |||
100 mg, n (%) | 15 (50%) | 20 (55.5%) | 6 (50%) | 10 (58.8%) | 5 (45.5%) | 8 (61.6%) | |||
150 mg, n (%) | 9 (30%) | 10 (27.8%) | 4 (33.3%) | 5 (29.4%) | 4 (36.4%) | 3 (23.1%) | |||
Diuretics, n (%) | 107 (100) | 100 (93.4) | 0.169 | 53 (100) | 49 (92.4) | 0.578 | 37 (100) | 33 (89.1) | 0.125 |
Beta-blokers | 104 (97.2) | 102 (95.3) | 0.521 | 53 (100) | 52 (98.1) | 0.465 | 35 (94.6) | 36 (97.3) | 0.661 |
Calcium antagonists, n (%) | 33 (30.8) | 30 (28.1) | 0.298 | 15 (28.3) | 14 (26.4) | 0.741 | 10 (27.1) | 9 (24.3) | 0.332 |
Anti-diabetic therapy | |||||||||
Insulin, n (%) | – | – | – | 10 (18.9) | 12 (22.6) | 0.560 | 8 (21.6) | 11 (29.7) | 0.282 |
Metformin, n (%) | – | – | 42 (79.2) | 46 (86.8) | 0.451 | 30 (81.1) | 32 (86.5) | 0.457 | |
DPP-IV inhibitor, n (%) | – | – | – | 12 (22.6) | 13 (24.5) | 0.332 | 10 (27.2) | 12 (32.4) | 0.368 |
GLP-1 agonist, n (%) | – | – | – | 7 (13.2) | 6 (11.3) | 0.599 | 4 (10.8) | 5 (13.5) | 0,446 |
Sulfonylureas, n (%) | – | – | – | 4 (7.5) | 0 | / | 2 (5.4) | 0 | – |
Glinides, n (%) | – | – | – | 6 (11.3) | 2 (3.8) | 4 (10.8) | 5 (13.5) | ||
Donor data | |||||||||
Mean age (years) | 33.1 ± 9.9 | – | – | 32.4 ± 10.7 | – | – | 31.9 ± 10.6 | – | – |
Male, n (%) | 50 (46.7) | – | – | 24 (45.2) | – | – | 18 (48.6) | – | – |
BMI, kg/m2 | 26.1 ± 1.1 | – | – | 25.9 ± 1.4 | – | – | 26.4 ± 1.0 | – | – |
Donor ischemic time (min) | 100.3 ± 19.9 | – | – | 101.1 ± 20.4 | – | – | 100.1 ± 13.6 | – | – |